You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to November 2024

AbstractFullPdf
Nov 2021412040
Dec 202178016
Jan 202294014
Feb 202292024
Mar 2022202022
Apr 2022154018
May 2022120021
Jun 202292017
Jul 202218609
Aug 2022146012
Sep 202294016
Oct 202286011
Nov 202296017
Dec 20229004
Jan 20236407
Feb 20235604
Mar 20238207
Apr 202350012
May 202370010
Jun 20234408
Jul 202368018
Aug 202364012
Sep 20239808
Oct 20238008
Nov 20239206
Dec 20238603
Jan 20242407
Feb 20245205
Mar 20248407
Apr 202496013
May 20248209
Jun 20246809
Jul 20246704
Aug 202482010
Sep 2024126012
Oct 202496013
Nov 20245208
Total36250441